1 / 19

Case Presentation

Case Presentation. December 19, 2007. 21 y.o. male CC: Right leg pain HPI: 1 year ago had surgery for a “tumor” on right leg. “Replaced my shin bone. But I don’t remember what they called it.”. PMH/PSH: as above NKDA Meds: None

shay
Télécharger la présentation

Case Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case Presentation • December 19, 2007

  2. 21 y.o. male • CC: Right leg pain • HPI: 1 year ago had surgery for a “tumor” on right leg. “Replaced my shin bone. But I don’t remember what they called it.”

  3. PMH/PSH: as above • NKDA • Meds: None • SHx: denies ETOH, TOB or illicit drug use, recently discharged from the Navy, swims for exercise, BA in nursing but currently on disability • FHx: N/C

  4. Pertinent Positives: • Well-healed scars on right shin, including skin graft site mid-shaft • Intact neurovascular exam • Imaging:

  5. Plain XR

  6. Allograft Nonunion • 8 – 17% reported • Lack of host-donor junction @ 1 year • Union = gap obliterated or bridging bone @ 3 or greater cortices on AP and Lateral imaging • Worse outcomes if: • Adjuvant chemotherapy • Adjuvant radiation • Infection – usually occurs in 1st year • Fracture – usually occurs in first 3 years • Original disease stage II or III (MTS) • Allograft is part of arthrodesis procedure

  7. Allograft Nonunion • Retrospective review 945 allograft patients: • 163 nonunion (17.3%) • No chemo, no XRT 11.3% • XRT only 18% • Chemo 27% • 162 revised: • 47% required further procedures for nonunion • 49 ultimate failures required metallic prosthesis, replacement of allograft or amputation Menken HJ et al, CORR 2001; 382: 87-98.

  8. Allograft Nonunion • 718 patients observed greater than 2 years: • 75% retained and successful for >20 years • 17% nonunion • 11% infection • 19% fracture • 6% unstable joint • Of the failed allografts: • >85% of the failures due to infection, fracture, recurrence of primary tumor • Susceptibility to infection primarily in 1st year • Susceptibility to fracture in first 3 years Menken HJ et al.; CORR, 1996; 324:86-97.

  9. Adamantinoma • 0.4 - 1% of all primary bone tumors • 2nd & 3rd decade; range 3-86 yrs • Pain, swelling in adolescent or young adult • 85 – 90% tibial shaft • 10% of these ipsilateral fibula • Femur, humerus, ulna, radius, hands/feet

  10. Adamantinoma • Mets in 12-29% • Lung, bone, regional lymph nodes • Mortality 13-18% • Survival with metastatic disease ~ 13 yrs • Risk factors: • Intra-lesional treatment • Male • Short duration of symptoms • Young age on presentation (<20 yrs) • Lack of squamous differentiation of tumor

  11. Adamantinoma - XR • Eccentric, cortical, diaphyseal, long bone • Sclerotic edge slowly growing lesion • Slight expansion of cortex with thinning • Cystic or multiloculated appearance • Lack of periosteal reaction, even in presence of extensive cortical destruction • Two most characteristic features: • Location in tibia • Intracortical involvement

  12. Adamantinoma • MRI: • T1 – isointense, enhances with gadolinium • T2 – hyper-intense

  13. Histology -Basiloid cells, pseudoglandular pattern and peripheral palisading, characteristic of an adamantinoma

  14. MTS System • Stage Grade* Site† Metastasis‡ • I A G1 T1 M0 • B G1 T2 M0 • II A G2 T1 M0 • B G2 T2 M0 • III G1 or G2 T1 or T2 M1 • *G1 = low grade and G2 = high grade. • †T1 = intracompartmental and T2 = extracompartmental. • ‡M0 = no regional or distant metastasis and M1 = regional or distant metastasis.

  15. AJCC Staging System

More Related